Vebanvibart is a humanized IgG1κ monoclonal antibody designed to target SARS-CoV-2, supplied with a Human IgG1κ Isotype Control. It is a research tool for in vitro neutralization assays and in vivo preclinical studies to investigate antiviral mechanisms and therapeutic potential.